Updated S2 K guidelines for the management of bullous
pemphigoid initiated by the European Academy of Dermatology and
Venereology (EADV)

J 2022

Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)

BORRADORI, L., N. VAN BEEKN, C. FELICIANI, B. TEDBIRT, E. ANTIGA et. al.

Základní údaje

Originální název

Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)

Autoři

BORRADORI, L. (garant), N. VAN BEEKN, C. FELICIANI, B. TEDBIRT, E. ANTIGA, R. BERGMAN, B. C. BOECKLE, M. CAPRONI, F. CAUX, N. S. CHANDRAN, G. CIANCHINI, M. DANESHPAZHOOH, D. DE, D. DIDONA, M. G. DI ZENZOM, M. DMOCHOWSKI, K. DRENOVSKA, J. EHRCHEN, M. GOEBELER, R. GROVES, C. GUENTHER, B. HORVATH, M. HERTL, S. HOFMANN, D. IOANNIDES, B. ITZLINGER-MONSHI, Hana JEDLIČKOVÁ (203 Česká republika, domácí), C. KOWALEWSKI, K. KRIDIN, Y. L. LIM, B. MARINOVIC, A. MARZANO, J -M. MASCARO, J. M. MEIJER, D. MURRELL, K. PATSATSI, C. PINCELLI, C. PROST, K. RAPPERSBERGER, M. SARDY, J. SETTERFIELD, M. SHAHID, E. SPRECHER, K. TASANEN, S. UZUN, S. VASSILEVA, K. VESTERGAARD, A. VOROBYEV, I. VUJIC, G. WANG, K. WOZNIAK, S. YAYLI, G. ZAMBRUNO, D. ZILLIKENS, E. SCHMIDT a P. JOLY

Vydání

JEADV - journal of the European Academy of Dermatology and Venereology, HOBOKEN, WILEY, 2022, 0926-9959

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30216 Dermatology and venereal diseases

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 9.200

Kód RIV

RIV/00216224:14110/22:00128444

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1111/jdv.18220

UT WoS

000818030100001

Klíčová slova anglicky

bullous pemphigoid; diagnostics; therapy

Štítky

14110125, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 3. 2. 2023 08:53, Mgr. Tereza Miškechová

Anotace

V originále

Background Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localized or, most frequently, generalized bullous lesions. A subset of patients only develops excoriations, prurigo-like lesions, and eczematous and/or urticarial erythematous lesions. The disease, which is significantly associated with neurological disorders, has high morbidity and severely impacts the quality of life. Objectives and methodology The Autoimmune blistering diseases Task Force of the European Academy of Dermatology and Venereology sought to update the guidelines for the management of BP based on new clinical information, and new evidence on diagnostic tools and interventions. The recommendations are either evidence-based or rely on expert opinion. The degree of consent among all task force members was included. Results Treatment depends on the severity of BP and patients' comorbidities. High-potency topical corticosteroids are recommended as the mainstay of treatment whenever possible. Oral prednisone at a dose of 0.5 mg/kg/day is a recommended alternative. In case of contraindications or resistance to corticosteroids, immunosuppressive therapies, such as methotrexate, azathioprine, mycophenolate mofetil or mycophenolate acid, may be recommended. The use of doxycycline and dapsone is controversial. They may be recommended, in particular, in patients with contraindications to oral corticosteroids. B-cell-depleting therapy and intravenous immunoglobulins may be considered in treatment-resistant cases. Omalizumab and dupilumab have recently shown promising results. The final version of the guideline was consented to by several patient organizations. Conclusions The guidelines for the management of BP were updated. They summarize evidence- and expert-based recommendations useful in clinical practice.

Citovat

BORRADORI, L., N. VAN BEEKN, C. FELICIANI, B. TEDBIRT, E. ANTIGA, R. BERGMAN, B. C. BOECKLE, M. CAPRONI, F. CAUX, N. S. CHANDRAN, G. CIANCHINI, M. DANESHPAZHOOH, D. DE, D. DIDONA, M. G. DI ZENZOM, M. DMOCHOWSKI, K. DRENOVSKA, J. EHRCHEN, M. GOEBELER, R. GROVES, C. GUENTHER, B. HORVATH, M. HERTL, S. HOFMANN, D. IOANNIDES, B. ITZLINGER-MONSHI, Hana JEDLIČKOVÁ, C. KOWALEWSKI, K. KRIDIN, Y. L. LIM, B. MARINOVIC, A. MARZANO, J -M. MASCARO, J. M. MEIJER, D. MURRELL, K. PATSATSI, C. PINCELLI, C. PROST, K. RAPPERSBERGER, M. SARDY, J. SETTERFIELD, M. SHAHID, E. SPRECHER, K. TASANEN, S. UZUN, S. VASSILEVA, K. VESTERGAARD, A. VOROBYEV, I. VUJIC, G. WANG, K. WOZNIAK, S. YAYLI, G. ZAMBRUNO, D. ZILLIKENS, E. SCHMIDT a P. JOLY. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). JEADV - journal of the European Academy of Dermatology and Venereology. HOBOKEN: WILEY, 2022, roč. 36, č. 10, s. 1689-1704. ISSN 0926-9959. Dostupné z: https://dx.doi.org/10.1111/jdv.18220.

@article{2251442,
   author = {Borradori, L. and Van BeekN, N. and Feliciani, C. and Tedbirt, B. and Antiga, E. and Bergman, R. and Boeckle, B. C. and Caproni, M. and Caux, F. and Chandran, N. S. and Cianchini, G. and Daneshpazhooh, M. and De, D. and Didona, D. and Di ZenzoM, M. G. and Dmochowski, M. and Drenovska, K. and Ehrchen, J. and Goebeler, M. and Groves, R. and Guenther, C. and Horvath, B. and Hertl, M. and Hofmann, S. and Ioannides, D. and ItzlingerandMonshi, B. and Jedličková, Hana and Kowalewski, C. and Kridin, K. and Lim, Y. L. and Marinovic, B. and Marzano, A. and Mascaro, J andM. and Meijer, J. M. and Murrell, D. and Patsatsi, K. and Pincelli, C. and Prost, C. and Rappersberger, K. and Sardy, M. and Setterfield, J. and Shahid, M. and Sprecher, E. and Tasanen, K. and Uzun, S. and Vassileva, S. and Vestergaard, K. and Vorobyev, A. and Vujic, I. and Wang, G. and Wozniak, K. and Yayli, S. and Zambruno, G. and Zillikens, D. and Schmidt, E. and Joly, P.},
   article_location = {HOBOKEN},
   article_number = {10},
   doi = {http://dx.doi.org/10.1111/jdv.18220},
   keywords = {bullous pemphigoid; diagnostics; therapy},
   language = {eng},
   issn = {0926-9959},
   journal = {JEADV - journal of the European Academy of Dermatology and Venereology},
   title = {Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)},
   url = {https://onlinelibrary.wiley.com/doi/10.1111/jdv.18220},
   volume = {36},
   year = {2022}
}

TY  - JOUR
ID  - 2251442
AU  - Borradori, L. - Van BeekN, N. - Feliciani, C. - Tedbirt, B. - Antiga, E. - Bergman, R. - Boeckle, B. C. - Caproni, M. - Caux, F. - Chandran, N. S. - Cianchini, G. - Daneshpazhooh, M. - De, D. - Didona, D. - Di ZenzoM, M. G. - Dmochowski, M. - Drenovska, K. - Ehrchen, J. - Goebeler, M. - Groves, R. - Guenther, C. - Horvath, B. - Hertl, M. - Hofmann, S. - Ioannides, D. - Itzlinger-Monshi, B. - Jedličková, Hana - Kowalewski, C. - Kridin, K. - Lim, Y. L. - Marinovic, B. - Marzano, A. - Mascaro, J -M. - Meijer, J. M. - Murrell, D. - Patsatsi, K. - Pincelli, C. - Prost, C. - Rappersberger, K. - Sardy, M. - Setterfield, J. - Shahid, M. - Sprecher, E. - Tasanen, K. - Uzun, S. - Vassileva, S. - Vestergaard, K. - Vorobyev, A. - Vujic, I. - Wang, G. - Wozniak, K. - Yayli, S. - Zambruno, G. - Zillikens, D. - Schmidt, E. - Joly, P.
PY  - 2022
TI  - Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)
JF  - JEADV - journal of the European Academy of Dermatology and Venereology
VL  - 36
IS  - 10
SP  - 1689-1704
EP  - 1689-1704
PB  - WILEY
SN  - 09269959
KW  - bullous pemphigoid
KW  - diagnostics
KW  - therapy
UR  - https://onlinelibrary.wiley.com/doi/10.1111/jdv.18220
N2  - Background Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localized or, most frequently, generalized bullous lesions. A subset of patients only develops excoriations, prurigo-like lesions, and eczematous and/or urticarial erythematous lesions. The disease, which is significantly associated with neurological disorders, has high morbidity and severely impacts the quality of life. Objectives and methodology The Autoimmune blistering diseases Task Force of the European Academy of Dermatology and Venereology sought to update the guidelines for the management of BP based on new clinical information, and new evidence on diagnostic tools and interventions. The recommendations are either evidence-based or rely on expert opinion. The degree of consent among all task force members was included. Results Treatment depends on the severity of BP and patients' comorbidities. High-potency topical corticosteroids are recommended as the mainstay of treatment whenever possible. Oral prednisone at a dose of 0.5 mg/kg/day is a recommended alternative. In case of contraindications or resistance to corticosteroids, immunosuppressive therapies, such as methotrexate, azathioprine, mycophenolate mofetil or mycophenolate acid, may be recommended. The use of doxycycline and dapsone is controversial. They may be recommended, in particular, in patients with contraindications to oral corticosteroids. B-cell-depleting therapy and intravenous immunoglobulins may be considered in treatment-resistant cases. Omalizumab and dupilumab have recently shown promising results. The final version of the guideline was consented to by several patient organizations. Conclusions The guidelines for the management of BP were updated. They summarize evidence- and expert-based recommendations useful in clinical practice.
ER  -

BORRADORI, L., N. VAN BEEKN, C. FELICIANI, B. TEDBIRT, E. ANTIGA, R. BERGMAN, B. C. BOECKLE, M. CAPRONI, F. CAUX, N. S. CHANDRAN, G. CIANCHINI, M. DANESHPAZHOOH, D. DE, D. DIDONA, M. G. DI ZENZOM, M. DMOCHOWSKI, K. DRENOVSKA, J. EHRCHEN, M. GOEBELER, R. GROVES, C. GUENTHER, B. HORVATH, M. HERTL, S. HOFMANN, D. IOANNIDES, B. ITZLINGER-MONSHI, Hana JEDLIČKOVÁ, C. KOWALEWSKI, K. KRIDIN, Y. L. LIM, B. MARINOVIC, A. MARZANO, J -M. MASCARO, J. M. MEIJER, D. MURRELL, K. PATSATSI, C. PINCELLI, C. PROST, K. RAPPERSBERGER, M. SARDY, J. SETTERFIELD, M. SHAHID, E. SPRECHER, K. TASANEN, S. UZUN, S. VASSILEVA, K. VESTERGAARD, A. VOROBYEV, I. VUJIC, G. WANG, K. WOZNIAK, S. YAYLI, G. ZAMBRUNO, D. ZILLIKENS, E. SCHMIDT a P. JOLY. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). \textit{JEADV - journal of the European Academy of Dermatology and Venereology}. HOBOKEN: WILEY, 2022, roč.~36, č.~10, s.~1689-1704. ISSN~0926-9959. Dostupné z: https://dx.doi.org/10.1111/jdv.18220.

Podrobný výpis o publikaci